[1] 万顺伦, 王炳旭, 丛志强. 老年期重症肌无力的临床特点[J]. 中华神经科杂志, 1998, 31(2):83-85.
[2] 宋宣克, 王林景, 冯怡锟, 等. 老年重症肌无力诊治分析[J]. 中国实用神经疾病杂志, 2021, 24(9):765-769.
[3] GENG Y, ZHANG H, WANG Y. Risk factors of myasthenia crisis after thymectomy among myasthenia gravis patients:a meta-analysis[J]. Medicine, 2020, 99(1):e18622.
[4] 谭群友, 陶绍霖, 刘宝东, 等. 重症肌无力外科治疗中国临床专家共识[J]. 中国胸心血管外科临床杂志, 2022, 29(5):529-539.
[5] 汤旎, 谷有全, 张晓燕, 等. 胸腺切除术后重症肌无力复发或疗效不佳的危险因素[J]. 临床神经病学杂志, 2019, 32(6):470-472.
[6] SOMNIER F E. Exacerbation of myasthenia gravis after removal of thymomas[J]. Acta Neurologica Scandinavica, 1994, 90(1):56-66.
[7] 王楠楠, 万顺伦. 影响老年重症肌无力免疫抑制治疗远期疗效的多因素分析[J]. 中华老年医学杂志, 2021, 40(3):356-358.
[8] 丛志强, 刘敏, 赵仁亮. 非手术免疫抑制疗法治疗伴胸腺瘤的重症肌无力患者的远期疗效观察[J]. 中华神经科杂志, 1999, 32(5):296-299.
[9] EVOLI A, BATOCCHI P, PALMISANI T, et al. Long-term results of corticosteroid therapy in patients with myasthenia gravis[J]. Eur Neurol, 1992, 32(1):37-43.
[10] OOSTERHUIS H J, LIMBURG P C, HUMMEL-TAPPEL E, et al. Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients[J]. J Neurol Sci, 1983, 58(3):371-385.
[11] ALKHAWAJAH N M, OGER J. Treatment of myasthenia gravis in the aged[J]. Drugs aging, 2015, 32(9):689-697.
[12] 徐文桢. 胸腺瘤与重症肌无力[J]. 中国实用内科杂志, 1994, 14(6):328-330.
[13] WAKATA N, FUJIOKA T, NISHINA M, et al. Myasthenia gravis and invasive thymoma. A 20-year experience[J]. Eur Neurol, 1993, 33(2):115-120.
[14] 丛志强. 伴胸腺瘤的重症肌无力的诊断和治疗[J]. 中华神经科杂志, 1997, 30(2):118-121.
[15] KONDO K, MONDEN Y. Thymoma and myasthenia gravis: a clinical study of 1, 089 patients from Japan[J]. Ann Thorac Surg, 2005, 79(1):219-224.
[16] 周中民, 于杨, 刘娥. 影响胸腺瘤合并重症肌无力患者术后预后的相关因素分析[J]. 山西医药杂志, 2021, 50(15):2299-2302. |
